RNA interference, or RNAi, has transformed how ATTR-CM is treated by targeting disease at its source. This session explains how Alnylam’s RNAi therapies work, what they do inside the body, and how TTR reduction translates into real clinical and quality-of-life benefits for patients.

Cardiologist and MD, PhD at Brigham and Women’s Hospital/Harbor Medical Associates, specializing in cardiovascular medicine with a focus on cardiac amyloidosis and advanced heart care. Educated at Vanderbilt and trained at Brigham and Women’s, he blends clinical excellence with patient-centered care.